Results 151 to 160 of about 17,703,275 (296)

Identification of Novel Therapeutic Agent Candidates Through High Throughput Screening With Chemical Library Based on Molecular Subclassification in Canine Histiocytic Sarcoma Cell Lines

Veterinary and Comparative Oncology, EarlyView.
ABSTRACT Effective chemotherapy for canine histiocytic sarcoma (CHS) has yet to be established. In our previous study, CHS cell lines were subclassified into two groups based on their gene expression profiles: Group A and Group B. This study aimed to identify novel therapeutic agents that are effective against each CHS subgroup, and we performed high ...
Hiroki Sakuma, Hirotaka Tomiyasu, Mari Takamiya, Yuko Goto‐Koshino, Atsushi Tsukamoto, Makoto Bonkobara, Masaru Okuda   +6 more
wiley   +1 more source

Ｄｌｌ４和ＶＥＧＦＲ在氧诱导视网膜病小鼠模型中的表达及意义

Zhongshan Daxue xuebao. Yixue kexue ban, 2015
摘 要： 【目的】 为了分析Ｄｌｌ４、 ＶＥＧＦＲ－１、 ＶＥＧＦＲ－２在视网膜新生血管中的表达，探讨Ｎｏｔｃｈ１－Ｄｌｌ４信号通路在氧诱导视网膜病小鼠新生血管形成中的作用。【方法】 选用鼠龄７ ｄ的 Ｃ５７ＢＬ／６Ｊ 新生鼠３０只，分成实验组和对照组。实验组１５只，在氧浓度为（７５±２）％的密闭容器中生长５ ｄ，回到室内正常空气中；对照组１５只，在室内正常空气中生长。两组各取产后７ ｄ（７ ｄ ｐｏｓｔ－ｐａｒｔｕｍ，ｐ７）、ｐ１２、ｐ１７新生鼠 ５只，摘除眼球，取视网膜提取ＲＮＡ，以ＲＴ－ＰＣＲ ...
doaj  

VEGF inhibitor‐induced vascular dysfunction involves redox‐sensitive PARP activation and SIRT1 disruption

Experimental Physiology, EarlyView.
Abstract Vascular endothelial growth factor receptor (VEGFR) inhibitors are effective antiangiogenic agents used in cancer therapy. However, they are associated with cardiovascular disease, including hypertension and vascular dysfunction. The molecular mechanisms underlying these cardiovascular toxicities are unclear, but oxidative stress might be ...
Karla B. Neves, Rheure Alves‐Lopes, Augusto C. Montezano, Rhian M. Touyz   +3 more
wiley   +1 more source

The effects of EPHA2 inhibition on VEGF, VEGFR-1 and VEGFR-2 in human malignant glioma cells [PDF]

, 2018
Brain tumor “glioblastoma multiforme (GBM)” is assigned under fourth pathologic grades (grade IV) of astrocytic tumor. Despite various advances in the treatment modalities, median survival rate of GBM patients remains low between 12 to 14 months with ...
Baharuddin, Wan Noor Ainun
core  

The role of extracellular vesicles in cell–cell crosstalk in cardiotoxicity

The Journal of Physiology, EarlyView.
Abstract figure legend Administration of a pharmacological agent can result in off‐target cardiotoxicity which can be driven by cell–cell crosstalk between healthy and dysfunctional cardiac cells. Extracellular vesicles (EVs) are lipid bilayer structures that can move biological cargo between cells, facilitating cell–cell crosstalk.
Gabriella Bachynskyj‐Bilas, Debbie J. Otto, Daniel Stratton, Katja Rietdorf, Daniel M. Johnson, Calum J. McMullen   +5 more
wiley   +1 more source

Quantitative Imaging of Pyruvate Metabolism in a Patient With Anaplastic Thyroid Cancer

Magnetic Resonance in Medicine, Volume 96, Issue 2, Page 826-838, August 2026.
ABSTRACT Purpose Magnetic resonance imaging using hyperpolarized (HP) [1‐13C]‐pyruvate enables assessment of pyruvate metabolism in vivo and offers new insight into metabolic changes in response to cancer therapy. Widely used semi‐quantitative metrics of pyruvate metabolism can be affected by physiological factors that are extrinsic to intracellular ...
James A. Bankson, Joshua S. Niedzielski, Collin J. Harlan, Yunyun Chen, Christopher M. Walker, Philip L. Lorenzi, Lin Tan, Vikas Kundra, Matthew E. Merritt, Mukundan Ragavan, Dawid Schellingerhout, Renjie He, Yao Ding, Sahana Datar, Qing Wang, Christine B. Peterson, Clifton D. Fuller, Vlad C. Sandulache, Stephen Y. Lai   +18 more
wiley   +1 more source

Immature B cell malignancies synthesize VEGF, VEGFR-1 (Flt-1) and VEGFR-2 (KDR)

, 2004
Expression of VEGF and VEGFR support a role for angiogenic pathways in the pathogenesis of some hematological malignances. Our goal was to determine if expression of these angiogenic molecules also extend to childhood precursor B cell acute lymphoblastic
Al-Hussein, Khalid, Bhatia, Kishor, I Gutiérrez, Marina, Sunnuqrut, Nadia, El-Obeid, Adila, Hussain, Azhar   +5 more
core  

Combination Therapy With Sintilimab and Anlotinib for Advanced Undifferentiated Pleomorphic Sarcoma: A Case Report and Literature Review

Clinical Case Reports, Volume 14, Issue 7, July 2026.
ABSTRACT This report describes the case of a 73‐year‐old woman with advanced undifferentiated pleomorphic sarcoma (UPS) who was intolerant to chemotherapy. Following amputation, she received sintilimab plus anlotinib and achieved a partial response with 76.6% tumor reduction.
Yan Chen, Ronghua Chu
wiley   +1 more source

Belzutifan for Metastatic TFE3‐Rearranged Renal Cell Carcinoma With Pulmonary Metastases: A Case Report

IJU Case Reports, Volume 9, Issue 4, July 2026.
ABSTRACT Introduction Belzutifan is effective in patients with previously treated advanced clear cell renal cell carcinoma. However, evidence for its use in non‐clear cell renal cell carcinoma remains limited. Case Presentation A 33‐year‐old Japanese woman underwent total nephrectomy for a 10‐cm renal tumor with lung metastases.
Kazutaka Nakamura, Akihiro Kumono, Yuki Kobari, Atsuko Seki, Takayuki Nakayama, Hironori Fukuda, Kazuhiko Yoshida, Junpei Iizuka, Yoji Nagashima, Toshio Takagi   +9 more
wiley   +1 more source

A Case of Acalculous Cholecystitis During Lenvatinib Plus Pembrolizumab Therapy for Advanced Renal Cell Carcinoma

IJU Case Reports, Volume 9, Issue 4, July 2026.
ABSTRACT Introduction Lenvatinib plus pembrolizumab is a standard first‐line therapy for advanced renal cell carcinoma (RCC), and acute acalculous cholecystitis is a rare adverse event. Case Presentation A 60‐year‐old woman with metastatic TFE3‐positive non–clear cell RCC, classified as poor risk by the International Metastatic RCC Database Consortium (
Erika Soga, Go Noguchi, Kota Kobayashi, Rio Shibata, Ryosuke Jikuya, Tomoyuki Tatenuma, Mitsuru Komeya, Hiroki Ito, Hisashi Hasumi, Kazuhide Makiyama   +9 more
wiley   +1 more source